DPP-4 inhibitors: pharmacological differences and their clinical implications

Bibliography

• American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33(Suppl 1):S62-9
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation (IDF). IDF Diabetes ATLAS. Sixth edition. Available from: http://www.idf.org/diabetesatlas/introduction [Last accessed 12 May 2014]
   Google Scholar
• Esposito K, Chiodini P, Capuano A, et al. Fracture risk and bone mineral density in metabolic syndrome: a meta-analysis. J Clin Endocrinol Metab 2013;98(8):3306-14
   PubMed Web of Science ®Google Scholar
• Esposito K, Chiodini P, Capuano A, et al. Metabolic syndrome and endometrial cancer: a meta-analysis. Endocrine 2014;45(1):28-36
   PubMed Web of Science ®Google Scholar
• Esposito K, Chiodini P, Capuano A, et al. Metabolic syndrome and postmenopausal breast cancer: systematic review and meta-analysis. Menopause 2013;20(12):1301-9
   PubMed Web of Science ®Google Scholar
• Esposito K, Chiodini P, Capuano A, et al. Colorectal cancer association with metabolic syndrome and its components: a systematic review with meta-analysis. Endocrine 2013;44(3):634-47
   PubMed Web of Science ®Google Scholar
• Esposito K, Chiodini P, Capuano A, et al. Effect of metabolic syndrome and its components on prostate cancer risk: meta-analysis. J Endocrinol Invest 2013;36(2):132-9
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes – 2013. Diabetes Care 2013;36(1):S11-66
   PubMed Web of Science ®Google Scholar
• Type 2 diabetes: the management of type 2 diabetes. NICE clinical guideline 87 (update of NICE clinical guideline 66). Available from: http://www.nice.org.uk/nicemedia/live/12165/44318/44318.pdf [Last accessed July 5 2013]
   Google Scholar
• Holst J, Knop F, Vilsboll T, et al. Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes. Diabetes Care 2011;34(Suppl 2):S251-7
   PubMed Web of Science ®Google Scholar
• Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003;26:2929-40
   PubMed Web of Science ®Google Scholar
• Verspohl EJ. Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther 2009;124:113-38
   PubMed Web of Science ®Google Scholar
• Holz GG, Kang G, Harbeck M, et al. Cell physiology of cAMP sensor Epac. J Physiol 2006;577:5-15
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-705
   PubMed Web of Science ®Google Scholar
• Neumiller JJ. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. J Am Pharm Assoc (2003) 2009;49(Suppl 1):S16-29
   PubMed Web of Science ®Google Scholar
• Kirby M, Yu DM, O’Connor S, et al. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. Clin Sci (Lond) 2009;118(1):31-41
   PubMed Web of Science ®Google Scholar
• Nauck MA. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med 2011;124:S3-S18
   PubMed Web of Science ®Google Scholar
• Richard KR, Shelburne JS, Kirk JK. Tolerability of dipeptidyl peptidase-4 inhibitors: a review. Clin Ther 2011;33(11):1609-29
   PubMed Web of Science ®Google Scholar
• Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007;298:194-206
   PubMed Web of Science ®Google Scholar
• Scheen AJ. A review of gliptins in 2011. Expert Opin Pharmacother 2012;13(1):81-99
   PubMed Web of Science ®Google Scholar
• Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab 2011;13(1):7-18
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 2010;12(8):648-58
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. Clin Pharmacokinet 2010;49(9):573-88
   PubMed Web of Science ®Google Scholar
• Havale SH, Pal M. Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes. Bioorg Med Chem 2009;17(5):1783-802
   PubMed Web of Science ®Google Scholar
• Ligueros-Saylan M, Foley JE, Schweizer A, et al. An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function, from a large pool database of phase II and III clinical trials. Diabetes Obes Metab 2010;12:495-509
   PubMed Web of Science ®Google Scholar
• Lankas GR, Leiting B, Roy RS, et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005;54(10):2988-94
   PubMed Web of Science ®Google Scholar
• Gupta V, Kalra S. Choosing a gliptin. Indian J Endocrinol Metab 2011;15(4):298-308
   PubMedGoogle Scholar
• Ahrén B, Schweizer A, Dejager S, et al. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab 2011;13(9):775-83
   PubMed Web of Science ®Google Scholar
• Nabeno M, Akahoshi F, Kishida H, et al. A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site. Biochem Biophys Res Commun 2013;434(2):191-6
   PubMed Web of Science ®Google Scholar
• Nicolaus M, Brödl J, Linke R, et al. Endogenous GLP-1 regulates postprandial glycemia in humans: relative contributions of insulin, glucagon, and gastric emptying. J Clin Endocrinol Metab 2011;96(1):229-36
   PubMed Web of Science ®Google Scholar
• Hjøllund KR, Deacon CF, Holst JJ. Dipeptidyl peptidase-4 inhibition increases portal concentrations of intact glucagon-like peptide-1 (GLP-1) to a greater extent than peripheral concentrations in anaesthetised pigs. Diabetologia 2011;54(8):2206-8
   PubMed Web of Science ®Google Scholar
• Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Drugs 2011;71:1441-67
   PubMed Web of Science ®Google Scholar
• Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. Clin Endocrinol Metab 2006;91(11):4612-19
   Google Scholar
• Balas B, Baig MR, Watson C, et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab 2007;92(4):1249-55
   PubMed Web of Science ®Google Scholar
• Hu P, Yin Q, Deckert F, et al. Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers. J Clin Pharmacol 2009;49(1):39-49
   PubMed Web of Science ®Google Scholar
• He YL, Yamaguchi M, Ito H, et al. Pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with type 2 diabetes. Int J Clin Pharmacol Ther 2010;48(9):582-95
   PubMed Web of Science ®Google Scholar
• Marfella R, Barbieri M, Grella R, et al. Effects of vildagliptin twice daily vs sitagliptin once daily on 24-hour acute glucose fluctuations. J Diabetes Complications 2010;24(2):79-83
   PubMed Web of Science ®Google Scholar
• Ahrén B, Foley JE, Ferrannini E, et al. Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care 2010;33(4):730-2
   PubMed Web of Science ®Google Scholar
• Christopher R, Covington P, Davenport M, et al. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. Clin Ther 2008;30(3):513-27
   PubMed Web of Science ®Google Scholar
• Heise T, Graefe-Mody EU, Hüttner S, et al. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab 2009;11(8):786-94
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Hissa MN, Garber AJ, et al. Saxagliptin 014 Study Group. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009;32(9):1649-55
   PubMed Web of Science ®Google Scholar
• Bose AK, Mocanu MM, Carr RD, et al. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005;54:146-51
   PubMed Web of Science ®Google Scholar
• Matsui T, Nishino Y, Takeuchi M, et al. Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product–receptor axis. Pharmacol Res 2011;63:383-8
   PubMed Web of Science ®Google Scholar
• Maeda S, Matsui T, Yamagishi S. Vildagliptin inhibits oxidative stress and vascular damage in streptozotocin-induced diabetic rats. Int J Cardiol 2012;158(1):171-3
   PubMed Web of Science ®Google Scholar
• Kröller-Schön S, Knorr M, Hausding M, et al. Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition. Cardiovasc Res 2012;96(1):140-9
   PubMed Web of Science ®Google Scholar
• Bao W, Morimoto K, Hasegawa T, et al. Orally administered dipeptidyl peptidase-4 inhibitor (alogliptin) prevents abdominal aortic aneurysm formation through an antioxidant effect in rats. J Vasc Surg 2014;59(4):1098-108
   PubMed Web of Science ®Google Scholar
• Oeseburg H, de Boer RA, Buikema H, et al. Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A. Arterioscler Thromb Vasc Biol 2010;30(7):1407-14
   PubMed Web of Science ®Google Scholar
• Ceriello A, Esposito K, Testa R, et al. The possible protective role of glucagon-like peptide 1 on endothelium during the meal and evidence for an “endothelial resistance” to glucagon-like peptide 1 in diabetes. Diabetes Care 2011;34(3):697-702
   PubMed Web of Science ®Google Scholar
• Rizzo MR, Barbieri M, Marfella R, et al. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012;35(10):2076-82
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bhatt DL, Braunwald E, et al. the SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369(14):1317-26
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Marx N, Kahn SE, et al. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial. Diab Vasc Dis Res 2013;10(4):289-301
   PubMed Web of Science ®Google Scholar
• White WB, Cannon CP, Heller SR, et al. the EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369(14):1327-35
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov. A service of the U.S. National Institutes of Health. Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure. NCT00894868. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00894868?term=Vildagliptin+left+ventricular&rank=1 [Last accessed October 4 2013]
   Google Scholar
• Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2014;24(7):689-97
   PubMed Web of Science ®Google Scholar
• Agarwal S, Parashar A, Menon V. Meta-analysis of the cardiovascular outcomes with dipeptidyl peptidase 4 inhibitors: validation of the current FDA mandate. Am J Cardiovasc Drugs 2014;14(3):191-207
   PubMed Web of Science ®Google Scholar
• Wu S, Hopper I, Skiba M, Krum H. Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants. Cardiovasc Ther 2014; [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Schweizer A, Dejager S, Foley JE, et al. Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population. Diabetes Obes Metab 2010;12(6):485-94
   PubMed Web of Science ®Google Scholar
• Johansen OE, Neubacher D, von Eynatten M, et al. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol 2012;11:3
   PubMed Web of Science ®Google Scholar
• Wolf R, Frederich R, Fiedorek F, et al. Evaluation of CV risk in the saxagliptin clinical trials. Diabetes 69th Scientific sessions [8-LB]; 2009
   Google Scholar
• Scheen AJ. DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials. Diabetes Metab 2012;38(2):89-101
   PubMed Web of Science ®Google Scholar
• Strain WD, Lukashevich V, Kothny W, et al. Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study. Lancet 2013;382(9890):409-16
   PubMed Web of Science ®Google Scholar
• Doucet J, Chacra A, Maheux P, et al. Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus. Curr Med Res Opin 2011;27:863-9
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Wilson C, Fleck P. Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study. Diabetes Obes Metab 2013;15(10):906-14
   PubMed Web of Science ®Google Scholar
• Ahrén B, Schweizer A, Dejager S, et al. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab 2009;94(4):1236-43
   PubMed Web of Science ®Google Scholar
• Fonseca V, Schweizer A, Albrecht D, et al. Addition of vildagliptin to insulin improves glycemic control in type 2 diabetes. Diabetologia 2007;50:1148-55
   PubMed Web of Science ®Google Scholar
• Fonseca V, Baron M, Shao Q, et al. Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus. Horm Metab Res 2008;40:427-30
   PubMed Web of Science ®Google Scholar
• Kothny W, Foley J, Kozlovski P, et al. Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2013;15:252-7
   PubMed Web of Science ®Google Scholar
• Lukashevich V, Schweizer A, Shao Q, et al. Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes Obes Metab 2011;13:947-54
   PubMed Web of Science ®Google Scholar
• Lukashevich V, Schweizer A, Foley JE, et al. Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment. Vasc Health Risk Manag 2013;9:21-8
   PubMedGoogle Scholar
• Vilsboll T, Rosenstock J, Yki-Jarvinen H, et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2010;12:167-77
   PubMed Web of Science ®Google Scholar
• Arnolds S, Dellweg S, Clair J, et al. Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Diabetes Care 2010;33:1509-15
   PubMed Web of Science ®Google Scholar
• Hollander P, Raslova K, Skjoth TV, et al. Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomised controlled trial. Diabetes Obes Metab 2011;13:268-75
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Rendell MS, Gross JL, et al. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1C without causing weight gain or increased hypoglycemia. Diabetes Obes Metab 2009;11:1145-52
   PubMed Web of Science ®Google Scholar
• Barnett AH, Charbonnel B, Li J, et al. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy. Clin Drug Investig 2013;33(10):707-17
   PubMed Web of Science ®Google Scholar
• Mazze RS, Strock E, Wesley D, et al. Characterizing glucose exposure for individuals with normal glucose tolerance using continuous glucose monitoring and ambulatory glucose profile analysis. Diabetes Technol Ther 2008;10:149-59
   PubMed Web of Science ®Google Scholar
• Picconi F, Di Flaviani A, Malandrucco I, et al. Impact of glycemic variability on cardiovascular outcomes beyond glycated hemoglobin. Evidence and clinical perspectives. Nutr Metab Cardiovasc Dis 2012;22:691-6
   PubMed Web of Science ®Google Scholar
• Standl E, Schnell O, Ceriello A. Postprandial hyperglycemia and glycemic variability. Should we care? Diabetes Care 2011;34(Supp 2):S120-7
   PubMedGoogle Scholar
• Monnier L, Colette C, Owens DR. Glycemic variability: the third component of the dysglycemia in diabetes. Is it important? How to measure it? J Diabetes Sci Technol 2008;2(6):1094-100
   PubMedGoogle Scholar
• Ceriello A. The glucose triad and its role in comprehensive glycaemic control: current status, future management. Int J Clin Pract 2010;64(12):1705-11
   PubMed Web of Science ®Google Scholar
• Rodbard D. Glycemic variability: measurement and utility in clinical medicine and research–one viewpoint. Diabetes Technol Ther 2011;13:1-4
   PubMedGoogle Scholar
• Ceriello A, Ihnat MA. ’Glycaemic variability’: a new therapeutic challenge in diabetes and the critical care setting. Diabet Med 2010;27(8):862-7
   PubMed Web of Science ®Google Scholar
• Ceriello A, Hanefeld M, Leiter L, et al. Postprandial glucose regulation and diabetic complications. Arch Intern Med 2004;164(19):2090-5
   PubMed Web of Science ®Google Scholar
• Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010;107(9):1058-70
   PubMed Web of Science ®Google Scholar
• Wang J, Alexanian A, Ying R, et al. Acute exposure to low glucose rapidly induces endothelial dysfunction and mitochondrial oxidative stress: role for AMP kinase. Arterioscler Thromb Vasc Biol 2012;32(3):712-20
   PubMed Web of Science ®Google Scholar
• Gogitidze Joy N, Hedrington MS, Briscoe VJ, et al. Effects of acute hypoglycemia on inflammatory and pro-atherothrombotic biomarkers in individuals with type 1 diabetes and healthy individuals. Diabetes Care 2010;33:1529-35
   PubMed Web of Science ®Google Scholar
• Ceriello A, Hanefeld M, Leiter L, et al. Postprandial glucose regulation and diabetic complications. Arch Intern Med 2004;164(19):2090-5
   PubMed Web of Science ®Google Scholar
• Ceriello A. Hyperglycemia and the vessel wall: the pathophysiological aspects on the atherosclerotic burden in patients with diabetes. Eur J Cardiovasc Prev Rehabil 2010;17(Suppl 1):S15-19
   PubMedGoogle Scholar
• Ceriello A, Esposito K, Piconi L, et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 2008;57(5):1349-54
   PubMed Web of Science ®Google Scholar
• Schisano B, Tripathi G, McGee K, et al. Glucose oscillations, more than constant high glucose, induce p53 activation and a metabolic memory in human endothelial cells. Diabetologia 2011;54:1219-26
   PubMed Web of Science ®Google Scholar
• Sakamoto M, Nishimura R, Irako T, et al. Comparison of vildagliptin twice daily vs sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study). Cardiovasc Diabetol 2012;11:92
   PubMed Web of Science ®Google Scholar
• Guerci B, Monnier L, Serusclat P, et al. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study. Diabetes Metab 2012;38(4):359-66
   PubMed Web of Science ®Google Scholar
• Barbieri M, Rizzo MR, Marfella R, et al. Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors. Atherosclerosis 2013;227(2):349-54
   PubMed Web of Science ®Google Scholar
• He YL, Foteinos G, Neelakantham S, et al. Differential effects of vildagliptin and glimepiride on glucose fluctuations in patients with type 2 diabetes mellitus assessed using continuous glucose monitoring. Diabetes Obes Metab 2013;15(12):1111-19
   PubMed Web of Science ®Google Scholar
• Capuano A, Sportiello L, Maiorino MI, et al. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy - focus on alogliptin. Drug Des Devel Ther 2013;7:989-1001
   PubMed Web of Science ®Google Scholar
• Raz I, Chen Y, Wu M, et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin 2008;24:537-50
   PubMed Web of Science ®Google Scholar
• Mikhail N. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes. Expert Opin Investig Drugs 2008;17(6):845-53
   PubMed Web of Science ®Google Scholar
• Cai L, Cai Y, Lu ZJ, et al. The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials. J Clin Pharm Ther 2012;37(4):386-98
   PubMed Web of Science ®Google Scholar
• Keating GM. Vildagliptin: a review of its use in type 2 diabetes mellitus. Drugs 2010;70(16):2089-112
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMA). Epar Xelevia. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000762/WC500057865.pdf [Last accessed 16 June 2014]
   Google Scholar
• Ligueros-Saylan M, Foley JE, Schweizer A, et al. An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials. Diabetes Obes Metab 2010;12(6):495-509
   PubMed Web of Science ®Google Scholar
• Mathieu C, Barnett AH, Brath H, et al. Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE). Int J Clin Pract 2013;67(10):947-56
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Cardiovascular effects of gliptins. Nat Rev Cardiol 2013;10(2):73-84
   PubMed Web of Science ®Google Scholar
• Willemen MJ, Mantel-Teeuwisse AK, Straus SM, et al. Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase. Diabetes Care 2011;34(2):369-74
   PubMed Web of Science ®Google Scholar
• Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011;141:150-6
   PubMed Web of Science ®Google Scholar